Radiopharm Theranostics Advances with Promising HER2 Antibody Therapy Study

Radiopharm Theranostics Limited ((AU:RAD)) announced an update on their ongoing clinical study.

Study Overview: Radiopharm Theranostics Limited is conducting a Phase 0/1 study titled ‘Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients With Advanced Solid Tumours.’ The study aims to evaluate the safety and tolerability of 177Lu-RAD202 in patients with HER2 expressing advanced solid tumors, marking a significant step in targeted cancer therapy.

Intervention/Treatment: The intervention being tested is 177Lu-RAD202, a radiolabeled antibody designed to target the HER2 gene mutation in advanced solid tumors. Its purpose is to determine the optimal dose for future studies and potentially offer a new treatment option for patients.

Study Design: This is an open-label, single-group assignment study focusing on treatment. It involves no masking, meaning both researchers and participants know the treatment being administered. The primary purpose is to assess treatment safety and establish a recommended dose for further research.

Study Timeline: The study began on February 7, 2025, with the latest update submitted on April 29, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is essential for stakeholders tracking the development.

Market Implications: This study update could positively impact Radiopharm Theranostics’ stock performance by demonstrating progress in their clinical pipeline, potentially boosting investor confidence. As the company advances in developing targeted cancer therapies, it may position itself favorably against competitors in the oncology sector.

The study is currently ongoing, with further details available on the ClinicalTrials portal.